104 results on '"Kirkels WJ"'
Search Results
2. Chirurgische behandeling van extraretroperitoneale metastasen van het testiscarcinoom
- Author
-
van Vledder, Mark, Kirkels, WJ (Wim), Verhoef, Cees, de Wilt, JHW, Surgery, and Urology
- Published
- 2011
3. Measuring disease specific quality of life in localized prostate cancer: the Dutch experience
- Author
-
Korfage, Ida, Bot, Marie-louise, Madalinska, JB, Kirkels, WJ (Wim), Litwin, MS, de Koning, Harry, Public Health, and Urology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 2003
4. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ cell tumors
- Author
-
Looijenga, LHJ (Leendert), Leeuw, HPJC, Oorschot, M, van Gurp, RJHLM (Ruud), Stoop, Hans, Gillis, Ad, de Gouveia Brazao, CA, Weber, RFA (Rob), Kirkels, WJ (Wim), van Dijk, Thamar, Lindern, Marieke, Valk, Peter, Lajos, G, Olah, E, Nesland, JM, Fossa, SD, Oosterhuis, Wolter, Pathology, Developmental Biology, Internal Medicine, Urology, Cell biology, and Hematology
- Published
- 2003
5. Molecular urine cytology by microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine
- Author
-
van Rhijn, BWG (Bas), Lurkin, Irene, Chopin, DK, Kirkels, WJ (Wim), Thiery, JP, Kwast, Theodorus, Radvanyi, F, Zwarthoff, Ellen, Pathology, and Urology
- Published
- 2003
6. Features and preliminary results of the Dutch centre of ERSPC. (Rotterdam, The Netherlands)
- Author
-
Roobol - Bouts, MJ, Kirkels, WJ (Wim), Schröder, Fritz, and Urology
- Published
- 2003
7. Molecular grading of urothelial cell carcinoma based on FGFR3 status and MIB-1 expression
- Author
-
van Rhijn, BWG (Bas), Vis, AN (André), Kwast, Theodorus, Kirkels, WJ (Wim), Radvanyi, F, Ooms, ECM, Chopin, DK, Boeve, Egbert, Jöbsis, AC, Zwarthoff, Ellen, Pathology, and Urology
- Published
- 2003
8. FGFR3 and p53 as molecular markers in the diagnosis of urothelial cell carcinoma
- Author
-
van Rhijn, BWG (Bas), Kwast, Theodorus, Vis, AN (André), Kirkels, WJ (Wim), Radvanyi, F, Chopin, DK, Zwarthoff, Ellen, Pathology, and Urology
- Published
- 2002
9. Hematurie
- Author
-
Bosch, Ruud, Kirkels, WJ (Wim), Mickisch, GHJ, Mulders, PFA, Schröder, Fritz, Bangma, C.H., and Urology
- Published
- 2002
10. Long-term graft survival after urological complications of 695 kidney transplantations
- Author
-
van Roijen, JH (Jan Herman), Kirkels, WJ (Wim), Zietse, R., Roodnat, J.I., Weimar, Willem, IJzermans, J.N.M., Developmental Biology, Urology, Internal Medicine, and Surgery
- Published
- 2001
11. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate
- Author
-
van Rhijn, BWG (Bas), Lurkin, Irene, Radvanyi, F, Kirkels, WJ (Wim), Kwast, Theodorus, Zwarthoff, Ellen, Pathology, and Urology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 2001
12. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment
- Author
-
Madalinska, JB, Bot, Marie-louise, de Koning, Harry, Kirkels, WJ (Wim), Maas, Paul, Schröder, Fritz, Public Health, and Urology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 2001
13. Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam cancer registry
- Author
-
Spapen, SJJC, Damhuis, Ronald, Kirkels, WJ (Wim), and Urology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 2000
14. The European randomized study of screening for prostate cancer (ERSPC): an update. Members of the ERSPC, section Rotterdam
- Author
-
Schröder, Fritz, Kranse, M, Rietbergen, JBW (John), Hoedemaeker, RF (Robert), Kirkels, WJ (Wim), Urology, and Pathology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 1999
15. Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer
- Author
-
Rietbergen, JBW (John), Kruger, AE, Hoedemaeker, RF (Robert), Bangma VERVALLEN, CH, Kirkels, WJ (Wim), Schröder, Fritz, Urology, and Pathology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 1998
16. Randomised trial of prostate cancer screening in the Netherlands: assessment of acceptance and motives for attendance
- Author
-
Nijs, HGT (Huub), Tordoir, DMR, Schuurman, JH, Kirkels, WJ (Wim), Schröder, Fritz, Erasmus School of Health Policy & Management, and Urology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 1997
17. Characteristics of prostate cancers detected in a population-based screening study (ERSPC data, Rotterdam region)
- Author
-
Rietbergen, JBW (John), Kirkels, WJ (Wim), Kranse, M, Schröder, Fritz, Schröder, F.H., and Urology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 1997
18. Two screening programmes for prostate cancer: Attendance and Accebtability
- Author
-
Nijs, HGT (Huub), Casparie, AF (Anton), Koning, H (Hedda), Bot, Marie-louise, Kirkels, WJ (Wim), Schröder, Fritz, Erasmus School of Health Policy & Management, Immunology, and Urology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 1995
19. THE CURRENT TNM-CLASSIFICATION OF BLADDER CARCINOMA-IS IT AS GOOD AS WE NEED IT TO BE?
- Author
-
Kotake, T., primary, Flanigan, RC, additional, Kirkels, WJ, additional, Matsumura, Y Homma Y, additional, Newling, DWW, additional, Prapotnich, D., additional, Richie, JP, additional, and Wallace, DNA, additional
- Published
- 1995
- Full Text
- View/download PDF
20. Short-term effects of population-based screening for prostate cancer on health-related quality of life.
- Author
-
Essink-Bot M, de Koning HJ, Nijs HGT, Kirkels WJ, van der Maas PJ, Schroder FH, Essink-Bot, M L, de Koning, H J, Nijs, H G, Kirkels, W J, van der Maas, P J, and Schröder, F H
- Abstract
Background: Population-based screening for prostate cancer is currently being evaluated in randomized clinical trials in the United States and in Europe. Side effects arising from the process of screening and from the earlier treatment of screen-detected prostate cancer may be important factors in the evaluation. To examine health-related quality of life (or health status) among men screened for prostate cancer, we conducted a longitudinal study of 626 attenders to the Rotterdam (The Netherlands) prostate cancer screening program and of 500 nonparticipants.Methods: Attenders of the screening program and nonparticipants completed self-assessment questionnaires (SF-36 [i.e., Medical Outcomes Study 36-Item Short-Form Health Survey] and EQ-5D [i.e., EuroQol measure for health-related quality of life] health surveys) to measure generic health status, as well as an additional questionnaire for anxiety and items relating to prostate cancer screening.Results: Physical discomfort during digital rectal examination and during transrectal ultrasound was reported by 181 (37%) of 491 men and by 139 (29%) of 487 men, respectively; discomfort during prostate biopsy was reported by 64 (55%) of 116 men. Mean scores for health status and anxiety indicated that the participants did not experience relevant changes in physical, psychological, and social functioning during the screening procedure. However, high levels of anxiety were observed throughout the screening process among men with a high predisposition to anxiety. Similar scores for anxiety predisposition were observed among attenders and nonparticipants.Conclusions: At the group level, we did not find evidence that prostate cancer screening induced important short-term health-status effects, despite the short-lasting side effects related to the biopsy procedure. However, subgroups may experience high levels of anxiety. The implication is that unfavorable health-status effects of prostate cancer screening occur mainly in the treatment phase. [ABSTRACT FROM AUTHOR]- Published
- 1998
- Full Text
- View/download PDF
21. Rotterdam randomized pilot studies of screening for prostate cancer -- an overview after 10 years.
- Author
-
Schröder FH, Roobol MJ, Damhuis RAM, de Koning HJ, Blijenberg BG, Van der Kwast TH, Kirkels WJ, and Bangma CH
- Published
- 2005
- Full Text
- View/download PDF
22. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
- Author
-
Aluwini S, van Rooij PH, Kirkels WJ, Jansen PP, Praag JO, Bangma CH, and Kolkman-Deurloo IK
- Published
- 2012
- Full Text
- View/download PDF
23. Does 'normal' aging imply urinary, bowel, and erectile dysfunction? A general population survey.
- Author
-
Korfage IJ, Roobol M, de Koning HJ, Kirkels WJ, Schröder FH, and Essink-Bot ML
- Published
- 2008
- Full Text
- View/download PDF
24. Outcomes of urinary diversion after surgery for locally advanced or locally recurrent rectal cancer with complete cystectomy; ileal and colon conduit.
- Author
-
Hagemans JAW, Voogt ELK, Rothbarth J, Nieuwenhuijzen GAP, Kirkels WJ, Boormans JL, Koldewijn EL, Richardson R, Verhoef C, Rutten HJT, and Burger JWA
- Subjects
- Aged, Anastomosis, Surgical, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local diagnosis, Neoplasm Staging, Rectal Neoplasms diagnosis, Retrospective Studies, Urinary Reservoirs, Continent, Colon surgery, Cystectomy methods, Ileum surgery, Neoplasm Recurrence, Local surgery, Rectal Neoplasms surgery, Urinary Bladder surgery, Urinary Diversion methods
- Abstract
Introduction: Surgery for locally advanced rectal cancer (LARC) or locally recurrent rectal cancer (LRRC) may require total pelvic exenteration with the need for urinary diversion. The aim of this study was to describe outcomes for ileal and colon conduits after surgery for LARC and LRRC., Methods: All consecutive patients from two tertiary referral centers who underwent total pelvic exenteration for LARC or LRRC between 2000 and 2018 with cystectomy and urinary reconstruction using an ileal or colon conduit were retrospectively analyzed. Short- (≤30 days) and long-term (>30 days) complications were described for an ileal and colon conduit., Results: 259 patients with LARC (n = 131) and LRRC (n = 128) were included, of whom 214 patients received an ileal conduit and 45 patients a colon conduit. Anastomotic leakage of the ileo-ileal anastomosis occurred in 9 patients (4%) after performing an ileal conduit. Ileal conduit was associated with a higher rate of postoperative ileus (21% vs 7%, p = 0.024), but a lower proportion of wound infections than a colon conduit (14% vs 31%, p = 0.006). The latter did not remain significant in multivariate analysis. No difference was observed in the rate of uretero-enteric anastomotic leakage, urological complications, mortality rates, major complications (Clavien-Dindo≥3), or hospital stay between both groups., Conclusion: Performing a colon conduit in patients undergoing total pelvic exenteration for LARC or LRRC avoids the risks of ileo-ileal anastomotic leakage and may reduce the risk of a post-operative ileus. Besides, there are no other differences in outcome for ileal and colon conduits., Competing Interests: Declaration of competing interest None., (Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
25. Total pelvic exenteration for locally advanced and locally recurrent rectal cancer in the elderly.
- Author
-
Hagemans JAW, Rothbarth J, Kirkels WJ, Boormans JL, van Meerten E, Nuyttens JJME, Madsen EVE, Verhoef C, and Burger JWA
- Subjects
- Age Factors, Aged, Anastomotic Leak etiology, Chemoradiotherapy, Adjuvant, Humans, Middle Aged, Neoadjuvant Therapy, Neoplasm Invasiveness, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local therapy, Neoplasm, Residual, Pelvic Exenteration mortality, Rectal Neoplasms pathology, Rectal Neoplasms therapy, Retrospective Studies, Survival Rate, Neoplasm Recurrence, Local surgery, Pelvic Exenteration adverse effects, Rectal Neoplasms surgery
- Abstract
Background: Total pelvic exenteration (TPE) is a radical approach for locally advanced rectal cancer (LARC) and locally recurrent rectal cancer (LRRC) in case of tumour invasion into the urogenitary tract. The aim of this study is to assess surgical and oncological outcomes of TPE for LARC and LRRC in elderly patients compared to younger patients., Methods: All patients who underwent TPE for LARC and LRRC between January 1990 and March 2017 were retrospectively analyzed. Patients aged <70 years were classified as younger and ≥70 years as elderly patients., Results: In total 126 patients underwent TPE, of whom 88 younger and 38 elderly patients. Elderly patients had a significantly higher number of ASA > II patients (p = 0.01). Indication for surgery LARC (n = 73) and LRRC (n = 53) did not differ significantly. The 30-day mortality rate was significantly higher (p = 0.01) in elderly (13%) compared to younger patients (3%). Elderly patients experienced more anastomotic leakage (p = 0.02). Median overall survival (OS) was 75 months [95%CI 37.1; 112.9] for elderly and 45 months [95%CI 22.4; 67.8] for younger patients (p = 0.77). The 5-year OS rate was 44% in both groups. Median disease specific survival (DSS) was 78 months [95%CI 69.1; 86.9] for elderly and 60 months [95%CI 36.6; 83.4] for younger patients (p = 0.34). The 5-year DSS rate was 57% and 49%, respectively., Conclusion: TPE is an invasive treatment for rectal cancer with high 30-day mortality in elderly patients. Oncological outcomes are similar in elderly and younger patients. Therefore, TPE should not be withheld because of high age only, but careful patient selection is needed., (Copyright © 2018. Published by Elsevier Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
26. Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911.
- Author
-
Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Alfred Witjes J, and Oosterlinck W
- Subjects
- Age Factors, Aged, Carcinoma, Transitional Cell pathology, Female, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Time Factors, Urinary Bladder Neoplasms pathology, Adjuvants, Immunologic administration & dosage, Adjuvants, Immunologic adverse effects, BCG Vaccine adverse effects, Carcinoma, Transitional Cell drug therapy, Maintenance Chemotherapy, Urinary Bladder Neoplasms drug therapy, Withholding Treatment statistics & numerical data
- Abstract
Objective: To determine the relationship of age to side-effects leading to discontinuation of treatment in patients with stage Ta-T1 non-muscle-invasive bladder cancer (NMIBC) treated with maintenance bacille Calmette-Guérin (BCG)., Patients and Methods: We evaluated toxicity for 487 eligible patients with intermediate- or high-risk Ta-T1 (without carcinoma in situ) NMIBC randomised to receive 3 years of maintenance BCG therapy (247 BCG alone and 240 BCG + isoniazid) in European Organisation for Research and Treatment of Cancer Genito-Urinary Group trial 30911. The percentage of patients who stopped for toxicity and the number of treatment cycles that they received were compared in four age groups, ≤60, 61-70, 71-75 and >75 years, using the Mantel-Haenszel chi-square test for trend., Results: The percentage of patients stopping BCG for toxicity was 17.9% in patients aged ≤60 years, 21.9% in patients aged 61-70 years, 22.9% in patients aged 71-75 years, and 16.4% in patients aged >75 years (P = 0.90). For both systemic and local side-effects, there was likewise no significant difference., Conclusion: In patients with intermediate- and high-risk Ta-T1 NMIBC treated with BCG, no differences in toxicity as a reason for stopping treatment were detected based on patient age., (© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
27. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
- Author
-
Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, and Oddens J
- Subjects
- Aged, Aged, 80 and over, Disease Progression, Female, Humans, Maintenance Chemotherapy, Male, Middle Aged, Neoplasm Staging, Prognosis, Risk Assessment methods, Survival Rate, Urinary Bladder Neoplasms mortality, Adjuvants, Immunologic therapeutic use, BCG Vaccine therapeutic use, Neoplasm Recurrence, Local prevention & control, Nomograms, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology
- Abstract
Background: There are no prognostic factor publications on stage Ta-T1 non-muscle-invasive bladder cancer (NMIBC) treated with 1-3 yr of maintenance bacillus Calmette-Guérin (BCG)., Objective: To determine prognostic factors in NMIBC patients treated with 1-3 yr of BCG after transurethral resection of the bladder (TURB), to derive nomograms and risk groups, and to identify high-risk patients who should be considered for early cystectomy., Design, Setting, and Participants: Data for 1812 patients were merged from two European Organization for Research and Treatment of Cancer randomized phase 3 trials in intermediate- and high-risk NMIBC., Intervention: Patients received 1-3 yr of maintenance BCG after TURB and induction BCG., Outcome Measurements and Statistical Analysis: Prognostic factors for risk of early recurrence and times to late recurrence, progression, and death were identified in a training data set using multivariable models and applied to a validation data set., Results and Limitations: With a median follow-up of 7.4 yr, 762 patients recurred; 173 progressed; and 520 died, 83 due to bladder cancer (BCa). Statistically significant prognostic factors identified by multivariable analyses were prior recurrence rate and number of tumors for recurrence, and tumor stage and grade for progression and death due to BCa. T1G3 patients do poorly, with 1- and 5-yr disease-progression rates of 11.4% and 19.8%, respectively, and 1- and 5-yr disease-specific death rates of 4.8% and 11.3%. Limitations include lack of repeat transurethral resection in high-risk patients and exclusion of patients with carcinoma in situ., Conclusions: NMIBC patients treated with 1-3 yr of maintenance BCG have a heterogeneous prognosis. Patients at high risk of recurrence and/or progression do poorly on currently recommended maintenance schedules. Alternative treatments are urgently required., Patient Summary: Non-muscle-invasive bladder cancer patients at high risk of recurrence and/or progression do poorly on currently recommended bacillus Calmette-Guérin maintenance schedules, and alternative treatments are urgently required., Trial Registration: Study 30911 was registered with the US National Cancer Institute clinical trials database (protocol ID: EORTC 30911). Study 30962 was registered at ClinicalTrials.gov, number NCT00002990; http://clinicaltrials.gov/ct2/show/record/NCT00002990., (Copyright © 2015 European Association of Urology. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
28. Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
- Author
-
Aluwini S, Busser WM, Alemayehu WG, Boormans JL, Kirkels WJ, Jansen PP, Praag JO, Bangma CH, and Kolkman-Deurloo IK
- Subjects
- Aged, Brachytherapy methods, Follow-Up Studies, Gastrointestinal Diseases etiology, Humans, Kallikreins blood, Male, Middle Aged, Prognosis, Prospective Studies, Prostate-Specific Antigen blood, Prostatic Neoplasms rehabilitation, Radiation Injuries etiology, Radiotherapy Dosage, Treatment Outcome, Urinary Retention etiology, Brachytherapy adverse effects, Prostatic Neoplasms radiotherapy, Quality of Life
- Abstract
Background and Purpose: The use of HDR brachytherapy (HDR-BT) as monotherapy for prostate cancer (PC) is increasing worldwide with good tumour control rates and acceptable toxicity. We report our results on toxicity and quality of life (QoL) after HDR-BT monotherapy for PC patients., Materials and Methods: 166 low- and intermediate-risk localized PC patients were treated with HDR-BT to a total dose of 38Gy in four fractions. Genitourinary (GU) and gastrointestinal (GI) toxicities were prospectively assessed using EORTC-RTOG questionnaires and physicians charts. QoL was evaluated using EORTC QLQ-PR25 questionnaires., Results: Three months after treatment, acute GU and GI toxicities were reported in 10.8% and 7.2%. Acute toxicity resolved within two months in the majority of patients (61%). Late grade ⩾ 2 GU and GI toxicity were reported in 19.7% and 3.3% of patients 12 months after HDR-BT. Mean QLQ-PR25 scores showed clinically relevant changes from baseline for urinary symptoms and sexual functioning. With a mean follow-up of 35 months, biochemical failure was observed in 2.4%. Overall survival at 60 months was 93.6% and cancer-specific survival was 100%., Conclusions: HDR-BT monotherapy for localized PC showed excellent clinical outcome and acceptable acute and late toxicity. Urinary symptoms and sexual function QoL decreased after treatment., (Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
29. Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.
- Author
-
van Rhijn BW, Musquera M, Liu L, Vis AN, Zuiverloon TC, van Leenders GJ, Kirkels WJ, Zwarthoff EC, Boevé ER, Jöbsis AC, Bapat B, Jewett MA, Zlotta AR, and van der Kwast TH
- Subjects
- Aged, Carcinoma, Transitional Cell genetics, Carcinoma, Transitional Cell mortality, DNA Mutational Analysis, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Male, Middle Aged, Polymerase Chain Reaction, Receptor, Fibroblast Growth Factor, Type 3 genetics, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms mortality, World Health Organization, Carcinoma, Transitional Cell classification, Carcinoma, Transitional Cell pathology, Neoplasm Grading methods, Urinary Bladder Neoplasms classification, Urinary Bladder Neoplasms pathology
- Abstract
Currently, the use of two classification systems for bladder cancer grade is advocated in clinical guidelines because the WHO2004 classification has not been sufficiently validated with biological markers and follow-up. The slides of 325 primary non-muscle invasive bladder cancers from three hospitals were reviewed by one uro-pathologist in two separate sessions for the WHO1973 (G1, G2 and G3) and 2004 (papillary urothelial neoplasm of low malignant potential (LMP), low-grade (LG) and high-grade (HG)) classifications. FGFR3 status was examined with PCR-SNaPshot analysis. Expression of Ki-67, P53 and P27 was analyzed by immuno-histochemistry. Clinical recurrence and progression were determined. We performed validation and cross-validation of the two systems for grade with molecular markers and clinical outcome. Multivariable analyses were done to predict prognosis and pT1 bladder cancer. Grade review resulted in 88 G1, 149 G2 and 88 G3 lesions (WHO1973) and 79 LMP, 101 LG and 145 HG lesions (WHO2004). Molecular validation of both grading systems showed that FGFR3 mutations were associated with lower grades whereas altered expression (Ki-67, P53 and P27) was found in higher grades. Clinical validation showed that the two classification systems were both significant predictors for progression but not for recurrence. Cross-validation of both WHO systems showed a significant stepwise increase in biological (molecular markers) and clinical (progression) potential along the line: G1-LG-G2-HG-G3. The LMP and G1 categories had a similar clinical and molecular profile. On the basis of molecular biology and multivariable clinical data, our results support a four-tiered grading system using the 1973 and 2004 WHO classifications with one low-grade (LMP/LG/G1) category that includes LMP, two intermediate grade (LG/G2 and HG/G2) categories and one high-grade (HG/G3) category.
- Published
- 2015
- Full Text
- View/download PDF
30. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
- Author
-
Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Witjes JA, and Oosterlinck W
- Subjects
- Age Factors, Aged, Aged, 80 and over, Carcinoma, Transitional Cell mortality, Carcinoma, Transitional Cell surgery, Chemotherapy, Adjuvant, Cystectomy methods, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Invasiveness pathology, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prognosis, Proportional Hazards Models, Risk Assessment, Survival Rate, Treatment Outcome, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms surgery, BCG Vaccine administration & dosage, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell pathology, Epirubicin administration & dosage, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology
- Abstract
Background: Although maintenance bacillus Calmette-Guérin (BCG) is the recommended treatment in high-risk non-muscle-invasive bladder cancer (NMIBC), its efficacy in older patients is controversial., Objective: To determine the effect of age on prognosis and treatment outcome in patients with stage Ta T1 NMIBC treated with maintenance BCG., Design, Setting, and Participants: A total of 957 patients with intermediate- or high-risk Ta T1 (without carcinoma in situ) NMIBC were randomized in European Organization for Research and Treatment of Cancer (EORTC) trial 30911 comparing six weekly instillations of epirubicin, BCG, and BCG plus isoniazid followed by three weekly maintenance instillations over 3 yr., Outcome Measurements and Statistical Analysis: Cox multivariate proportional hazards regression models were used to assess the relative importance of age for recurrence, progression, overall survival, and NMIBC-specific survival with adjustment for EORTC risk scores., Results and Limitations: Overall, 822 eligible patients were included: 546 patients in the BCG with or without INH arms and 276 in the epirubicin arm. In patients treated with BCG with or without INH, 34.1% were >70 yr of age and 3.7% were >80 yr. With a median follow-up of 9.2 yr, patients >70 yr had a shorter time to progression (p=0.028), overall survival (p<0.001), and NMIBC-specific survival (p=0.049) after adjustment for EORTC risk scores in the multivariate analysis. The time to recurrence was similar compared with the younger patients. BCG was more effective than epirubicin for all four end points considered, and there was no evidence that BCG was any less effective compared with epirubicin in patients >70 yr., Conclusions: In intermediate- and high-risk Ta T1 urothelial bladder cancer patients treated with BCG, patients >70 yr of age have a worse long-term prognosis; however, BCG is more effective than epirubicin independent of patient age., Patient Summary: Intravesical bacillus Calmette-Guérin for non-muscle-invasive bladder cancer is less effective in patients >70 yr of age, but it is still more effective than epirubicin., Trial Registration: This study was registered with the US National Cancer Institute clinical trials database (protocol ID: EORTC 30911; http://www.cancer.gov/clinicaltrials/search/view?cdrid=77075&version=HealthProfessional&protocolsearchid=12442243#StudyIdInfo_CDR0000077075)., (Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
31. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: Long-term results [corrected].
- Author
-
Aluwini S, van Rooij PH, Kirkels WJ, Boormans JL, Kolkman-Deurloo IK, and Wijnmaalen A
- Subjects
- Adult, Aged, Aged, 80 and over, Combined Modality Therapy methods, Cystectomy methods, Cystectomy mortality, Disease-Free Survival, Female, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Organ Sparing Treatments mortality, Organs at Risk radiation effects, Prospective Studies, Rectum radiation effects, Urinary Bladder radiation effects, Urinary Bladder surgery, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms pathology, Brachytherapy methods, Organ Sparing Treatments methods, Urinary Bladder Neoplasms radiotherapy, Urinary Bladder Neoplasms surgery
- Abstract
Purpose: To report long-term results of a bladder preservation strategy for muscle-invasive bladder cancer (MIBC) using external beam radiation therapy and brachytherapy/interstitial radiation therapy (IRT)., Methods and Materials: Between May 1989 and October 2011, 192 selected patients with MIBC were treated with a combined regimen of preoperative external beam radiation therapy and subsequent surgical exploration with or without partial cystectomy and insertion of source carrier tubes for afterloading IRT using low dose rate and pulsed dose rate. Data for oncologic and functional outcomes were prospectively collected. The primary endpoints were local recurrence-free survival (LRFS), bladder function preservation survival, and salvage cystectomy-free survival. The endpoints were constructed according to the Kaplan-Meier method., Results: The mean follow-up period was 105.5 months. The LRFS rate was 80% and 73% at 5 and 10 years, respectively. Salvage cystectomy-free survival at 5 and 10 years was 93% and 85%. The 5- and 10-year overall survival rates were 65% and 46%, whereas cancer-specific survival at 5 and 10 years was 75% and 67%. The distant metastases-free survival rate was 76% and 69% at 5 and 10 years. Multivariate analysis revealed no independent predictors of LRFS. Radiation Therapy Oncology Group grade ≥3 late bladder and rectum toxicity were recorded in 11 patients (5.7%) and 2 patients (1%), respectively., Conclusions: A multimodality bladder-sparing regimen using IRT offers excellent long-term oncologic outcome in selected patients with MIBC. The late toxicity rate is low, and the majority of patients preserve their functional bladder., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
32. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
- Author
-
Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, and Schröder FH
- Subjects
- Aged, Biopsy, Disease Progression, Disease-Free Survival, Humans, Male, Middle Aged, Netherlands epidemiology, Predictive Value of Tests, Prognosis, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Prostatic Neoplasms therapy, Regression Analysis, Risk Factors, Time Factors, Kallikreins blood, Mass Screening methods, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnosis
- Abstract
Background: Evidence from randomized trials on the effects of screening for prostate cancer (PCa) on disease-specific mortality accumulates slowly with increasing follow-up., Objective: To assess data on PCa-specific mortality in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial., Design, Setting, and Participants: A randomized controlled trial with randomization after signed, written informed consent (efficacy trial). In the period 1993-1999, a total of 42 376 men aged 54-74 yr were randomized to a screening arm (S-arm) (n = 21 210 with screening every 4 yr, applying a total prostate-specific antigen [PSA] level cut-off ≥ 3.0 ng/ml as biopsy indication) or a control arm (C-arm) (n = 21 166; no intervention)., Outcome Measurements and Statistical Analysis: Number of PCas detected per arm depicted by predefined time periods and prognostic groups. PCa-specific mortality analyses using Poisson regression in age group 55-74 yr at randomization and separately in the predefined age group of 55-69 yr., Results and Limitations: After a median follow-up of 12.8 yr, 19 765 men (94.2%) were screened at least once and 2674 PCas were detected (of which 561 [21.0%] were interval PCas). In the C-arm, 1430 PCas were detected, resulting in an excess incidence of 59 PCas per 1000 men randomized (61 PCas per 1000 in age group 55-69 yr). Thirty-two percent of all men randomized have died. PCa-specific mortality relative-risk (RR) reductions of 20.0% overall (age: 55-74 yr; p = 0.042) and 31.6% (age: 55-69 yr; p = 0.004) were found. A 14.1% increase was found in men aged 70-74 yr (not statistically significant). Absolute PCa mortality was 1.8 per 1000 men randomized (2.6 per 1000 men randomized in age group 55-69 yr). The number needed to invite and number needed to manage were 565 and 33, respectively, for age group 55-74 yr, and 392 and 24, respectively, for age group 65-69 yr. Given the slow natural history of the disease, follow-up might be too short., Conclusions: Systematic PSA-based screening reduced PCa-specific mortality by 32% in the age range of 55-69 yr. The roughly twofold higher incidence in the S-arm underlines the importance of tools to better identify those men who would benefit from screening., (Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
33. Comparison of 30-day, 90-day and in-hospital postoperative mortality for eight different cancer types.
- Author
-
Damhuis RA, Wijnhoven BP, Plaisier PW, Kirkels WJ, Kranse R, and van Lanschot JJ
- Subjects
- Hospital Mortality, Humans, Neoplasms surgery, Netherlands epidemiology, Registries, Survival Analysis, Neoplasms mortality, Postoperative Complications mortality
- Abstract
Background: Various definitions are used to calculate postoperative mortality. As variation hampers comparability between reports, a study was performed to evaluate the impact of using different definitions for several types of cancer surgery., Methods: Population-based data for the period 1997-2008 were retrieved from the Rotterdam Cancer Registry for resectional surgery of oesophageal, gastric, colonic, rectal, breast, lung, renal and bladder cancer. Postoperative deaths were tabulated as 30-day, in-hospital or 90-day mortality. Postdischarge deaths were defined as those occurring after discharge from hospital but within 30 days., Results: This study included 40,474 patients. Thirty-day mortality rates were highest after gastric (8·8 per cent) and colonic (6·0 per cent) surgery, and lowest after breast (0·2 per cent) and renal (2·0 per cent) procedures. For most tumour types, the difference between 30-day and in-hospital rates was less than 1 per cent. For bladder and oesophageal cancer, however, the in-hospital mortality rate was considerably higher at 5·1 per cent (+1·3 per cent) and 7·3 per cent (+2·8 per cent) respectively. For gastric, colonic and lung cancer, 1·0 per cent of patients died after discharge. For gastric, lung and bladder cancer, more than 3 per cent of patients died between discharge and 90 days., Conclusion: The 30-day definition is recommended as an international standard because it includes the great majority of surgery-related deaths and is not subject to discharge procedures. The 90-day definition, however, captures mortality from multiple causes; although this may be of less interest to surgeons, the data may be valuable when providing information to patients before surgery., (Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
34. Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review.
- Author
-
Zuiverloon TC, Nieuweboer AJ, Vékony H, Kirkels WJ, Bangma CH, and Zwarthoff EC
- Subjects
- Administration, Intravesical, BCG Vaccine adverse effects, Biomarkers, Tumor genetics, Evidence-Based Medicine, Humans, Immunotherapy adverse effects, Patient Selection, Predictive Value of Tests, Treatment Outcome, Urinary Bladder Neoplasms chemistry, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms immunology, Urinary Bladder Neoplasms pathology, BCG Vaccine administration & dosage, Biomarkers, Tumor analysis, Immunotherapy methods, Urinary Bladder Neoplasms therapy
- Abstract
Context: Currently, bacillus Calmette-Guérin (BCG) intravesical instillations are standard treatment for patients with high-grade non-muscle-invasive bladder cancer; however, no markers are available to predict BCG response., Objective: To review the contemporary literature on markers predicting BCG response, to discuss the key issues concerning the identification of predictive markers, and to provide recommendations for further research studies., Evidence Acquisition: We performed a systematic review of the literature using PubMed and Embase databases in the period 1996-2010. The free-text search was extended by adding the following keywords: recurrence, progression, survival, molecular marker, prognosis, TP53, Ki-67, RB, fibronectin, immunotherapy, cytokine, interleukin, natural killer, macrophage, PMN, polymorphism, SNP, single nucleotide polymorphism, and gene signature., Evidence Synthesis: If thresholds for the detection of urinary interleukin (IL)-8, IL-18, and tumour necrosis factor apoptosis-inducing ligand levels are standardised, measurement of these cytokines holds promise in the assessment of BCG therapy outcome. Studies on immunohistochemical markers (ie, TP53, Ki-67, and retinoblastoma) display contradictory results, probably because of the small patient groups that were used and seem unsuitable to predict BCG response. Exploring combinations of protein levels might prove to be more helpful to establish the effect of BCG therapy. Single nucleotide polymorphisms, either in cytokines or in genes involved in DNA repair, need to be investigated in different ethnicities before their clinical relevance can be determined. Measurement of urinary IL-2 levels seems to be the most potent marker of all the clinical parameters reviewed., Conclusions: IL-2 levels are currently the most promising predictive markers of BCG response. For future studies focusing on new biomarkers, it is essential to make more use of new biomedical techniques such as microRNA profiling and genomewide sequencing., (Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
35. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer.
- Author
-
van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boevé ER, Jöbsis AC, Zwarthoff EC, and van der Kwast TH
- Subjects
- Aged, Female, Humans, Male, Neoplasm Invasiveness, Prognosis, Retrospective Studies, Risk Assessment, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology
- Abstract
Background: The European Organization for Research and Treatment of Cancer (EORTC) risk scores are not validated in an independent patient population. Molecular grade (mG) based on fibroblast growth factor receptor 3 (FGFR3) gene mutation status and MIB-1 expression was proposed as an alternative to pathologic grade in bladder cancer (BCa) [1]., Objective: To validate the EORTC risk score and to determine its relation to mG in a series with long-term follow-up as well as to determine reproducibility of pathologic grade and mG., Design, Setting, and Participants: In this multicenter study, we included 230 patients with primary non-muscle-invasive BCa (NMIBC)., Measurements: Four uropathologists reviewed the slides. FGFR3 mutation status was examined by two assays. MIB-1 was assessed by immunohistochemistry. The EORTC risk scores for recurrence and progression were determined. Multivariable analyses were used to find prognostic factors., Results and Limitations: Median follow-up was 8.62 yr (interquartile range: 6.6-11.8). FGFR3 mutations were significantly related to favorable disease parameters, whereas altered MIB-1 was frequently seen with pT1, high grade, and high EORTC risk scores. EORTC risk scores were significant in multivariable analyses for recurrence and progression. In multivariable analyses for progression and disease-specific survival, the mG had independent significance. The addition of mG to the multivariable model for progression increased the predictive accuracy from 74.9% to 81.7% (p<0.001; Mantel-Haenszel test). The mG (89%) was more reproducible than the pathologic grade (41-74%)., Conclusions: We validated the EORTC risk scores for primary NMIBC in a clinical and biomarker setting. Next to EORTC risk score, mG proved highly reproducible and predictive. Our long-term results justify an independent prospective analysis of mG and EORTC risk scores., ((c) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
36. Cervical lymph node dissection for metastatic testicular cancer.
- Author
-
van Vledder MG, van der Hage JA, Kirkels WJ, Oosterhuis JW, Verhoef C, and de Wilt JH
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Follow-Up Studies, Head and Neck Neoplasms secondary, Hospitals, University, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Testicular Neoplasms drug therapy, Testicular Neoplasms pathology, Treatment Outcome, Head and Neck Neoplasms surgery, Neck Dissection methods, Testicular Neoplasms surgery
- Abstract
Introduction: Despite high response rates to systemic chemotherapy, 30% of patients with advanced stage testicular carcinoma will have extra-retroperitoneal residual masses that require resection. Most often, these are located in the lungs and mediastinum and neck. Limited data are available concerning the incidence, surgical management, and follow-up of neck metastasis arising from a testicular primary tumor., Methods: We retrospectively reviewed all 665 patients who were referred to a tertiary referral center with the diagnosis of testicular cancer from January 1997 to June 2009 for the presence of cervical metastases. Patients who underwent concomitant surgical therapy were identified and analyzed. Clinical and pathological data were collected from patient records, including radiology and pathology reports. Furthermore, data on primary treatment strategy, chemotherapeutic regimens, timing of surgical procedures, complications, disease recurrence, and follow-up were collected., Results: Twenty-six patients (4%) had cervical lymph node metastasis. The majority (n = 19) had multiple ERP sites. Nine patients (35%) underwent selective neck dissection: in six patients, this was indicated because of residual masses after chemotherapy, and in three patients, cervical masses represented a late and distant relapse of previously treated disease. Viable cancer cells were present in the resected specimen only in these three patients. Seven patients are currently without evidence of disease. Two patients died of disseminated disease., Conclusions: Cervical lymph node metastases originating from testicular cancer are rare but are more commonly observed in patients with advanced stage disease. Selective neck dissection can be safely performed both after chemotherapy and in the case of recurrent disease.
- Published
- 2010
- Full Text
- View/download PDF
37. The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.
- Author
-
van Rhijn BW, van Leenders GJ, Ooms BC, Kirkels WJ, Zlotta AR, Boevé ER, Jöbsis AC, and van der Kwast TH
- Subjects
- Aged, Carcinoma mortality, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local epidemiology, Observer Variation, Prognosis, Reproducibility of Results, Risk Assessment, Urinary Bladder Neoplasms mortality, World Health Organization, Carcinoma classification, Carcinoma pathology, Disease Progression, Urinary Bladder Neoplasms classification, Urinary Bladder Neoplasms pathology
- Abstract
Background: A new grading system for bladder cancer (BCa) was adopted in 2004 to reduce observer variability and provide better prognostic information., Objective: We compared the World Health Organization (WHO) 1973 and 2004 systems for observer variability and prognosis., Design, Setting, and Participants: Slides of 173 primary non-muscle-invasive BCa were reviewed two times by four pathologists., Measurements: Intra- and interobserver variability were assessed using κ statistics. We determined the mean grade (eg, G1/low malignant potential is 1 grade point, G2/low grade is 2 grade points) of the pathologists per grading cycle. Kaplan-Meier analyses were applied for prediction of recurrence and progression., Results and Limitations: For WHO 2004 and 1973 grading, the agreement between the pathologists was 39-74% (κ: 0.14-0.58) and 39-64% (κ: 0.15-0.41), respectively. The intraobserver agreement varied from 71% to 88% (κ: 0.55-0.81). The mean grade of a pathologist was constant (difference below 0.1 grade point) irrespective of the grading system. Conversely, mean-grade differences among the pathologists were high, up to 0.7 grade point. The mean grades for the WHO 2004 system were 0.3-0.5 grade point higher than those of WHO 1973. Mean grade distinguished low and high graders among the pathologists and was strongly linked with risk of progression in each grade category., Conclusions: The variation in mean grade among individual pathologists exceeded the grade shift caused by WHO 2004 grading. Knowledge of the pathologist's mean grade allows a better assessment of the prognostic value of grading. Mean grade has the potential to become a tool for quality assurance in pathology., (Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
38. Controversies in the treatment of high-risk prostate cancer--what is the optimal combination of hormonal therapy and radiotherapy: a review of literature.
- Author
-
Al-Mamgani A, Lebesque JV, Heemsbergen WD, Tans L, Kirkels WJ, Levendag PC, and Incrocci L
- Subjects
- Androgen Antagonists therapeutic use, Combined Modality Therapy, Dose-Response Relationship, Radiation, Drug Administration Schedule, Humans, Male, Radiotherapy Dosage, Carcinoma drug therapy, Carcinoma radiotherapy, Prostatic Neoplasms drug therapy, Prostatic Neoplasms radiotherapy
- Abstract
Background: In high-risk prostate carcinoma, there is controversy whether these patients should be treated with escalated-dose (> or =74 Gy) or conventional-dose radiotherapy (<74 Gy) combined with hormonal therapy. Furthermore, the issue of the optimal duration and timing of hormonal therapy are not well crystallized., Patients and Methods: A search for evidence from randomized- and large non-randomized studies in order to address these issues, was therefore initiated. For this purpose, MedLine, EMbase, and PubMed and the data base of the Dutch randomized dose-escalation trial, were consulted., Results and Conclusions: From this search it was concluded that the benefit of hormonal therapy in combination with conventional-dose radiotherapy (<74 Gy) in high-risk prostate cancer is evident (Level 2 evidence); Levels 2 and 3 evidence were provided by several studies supporting the use of escalated-dose radiotherapy in high-risk prostate cancer. For the combination of hormonal therapy with escalated-dose radiotherapy in these patients, there is Level 2 evidence for moderately escalated dose (74 Gy) and high escalated dose (> or =78 Gy). The optimal duration and timing of hormonal therapy are not well defined. More randomized-controlled trials and meta-analyses are therefore needed to clearly determine the independent role of dose-escalation in high-risk patients treated with hormonal therapy and the optimal duration and timing of hormonal therapy.
- Published
- 2010
- Full Text
- View/download PDF
39. CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance.
- Author
-
Aluwini S, van Rooij P, Hoogeman M, Bangma C, Kirkels WJ, Incrocci L, and Kolkman-Deurloo IK
- Subjects
- Aged, Feasibility Studies, Humans, Male, Neoplasm Staging, Prostatic Neoplasms pathology, Stereotaxic Techniques, Prostatic Neoplasms radiotherapy
- Abstract
Purpose: The CyberKnife (CK), a linear accelerator mounted on a robotic device, enables excellent dose conformation to the target and minimizes dose to surrounding normal tissue. It is a very suitable device for performing hypofractionated stereotactic body radiotherapy as monotherapy for low- to intermediate-risk prostate cancer patients. We report our early experience using this technique., Materials and Methods: Between June 2008 and June 2009, 10 patients underwent CK monotherapy as treatment for their prostate cancer (stage
- Published
- 2010
- Full Text
- View/download PDF
40. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
- Author
-
Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, and de Reijke TM
- Subjects
- Administration, Intravesical, Aged, Aged, 80 and over, Carcinoma, Transitional Cell pathology, Drug Therapy, Combination, Humans, Middle Aged, Neoplasm Staging, Risk Assessment, Time Factors, Urinary Bladder Neoplasms pathology, Adjuvants, Immunologic administration & dosage, Antibiotics, Antineoplastic administration & dosage, BCG Vaccine administration & dosage, Carcinoma, Transitional Cell drug therapy, Epirubicin administration & dosage, Isoniazid administration & dosage, Urinary Bladder Neoplasms drug therapy
- Abstract
Background: Intravesical chemotherapy and bacillus Calmette-Guérin (BCG) reduce the recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit of BCG relative to chemotherapy for long-term end points is controversial, especially in intermediate-risk patients., Objective: The aim of the study was to compare the long-term efficacy of BCG and epirubicin., Design, Setting, and Participants: From January 1992 to February 1997, 957 patients with intermediate- or high-risk stage Ta T1 urothelial bladder cancer were randomized after transurethral resection to one of three treatment groups in the European Organization for Research and Treatment of Cancer Genito-Urinary Group phase 3 trial 30911., Intervention: Patients received six weekly instillations of epirubicin, BCG, or BCG plus isoniazid (INH) followed by three weekly maintenance instillations at months 3, 6, 12, 18, 24, 30, and 36., Measurements: End points were time to recurrence, progression, distant metastases, overall survival, and disease-specific survival., Results and Limitations: With 837 eligible patients and a median follow-up of 9.2 yr, time to first recurrence (p<0.001), distant metastases (p=0.046), overall survival (p=0.023), and disease-specific survival (p=0.026) were significantly longer in the two BCG arms combined as compared with epirubicin; however, there was no difference for progression. Three hundred twenty-three patients with stage T1 or grade 3 tumors were high risk, and the remaining 497 patients were intermediate risk. The observed treatment benefit was at least as large, if not larger, in the intermediate-risk patients compared with the high-risk patients., Conclusions: In patients with intermediate- and high-risk stage Ta and T1 urothelial bladder cancer, intravesical BCG with or without INH is superior to intravesical epirubicin not only for time to first recurrence but also for time to distant metastases, overall survival, and disease-specific survival. The benefit of BCG is not limited to just high-risk patients; intermediate-risk patients also benefit from BCG., Trial Registration: This study was registered with the US National Cancer Institute clinical trials database [protocol ID: EORTC-30911]. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=77075&version=HealthProfessional&protocolsearchid=6540260., (Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
41. Total pelvic exenteration for primary and recurrent malignancies.
- Author
-
Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, and de Wilt JH
- Subjects
- Adult, Aged, Brachytherapy methods, Cohort Studies, Disease-Free Survival, Endometrial Neoplasms mortality, Endometrial Neoplasms pathology, Endometrial Neoplasms radiotherapy, Endometrial Neoplasms surgery, Female, Hospital Mortality trends, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local radiotherapy, Neoplasm Staging, Pelvic Exenteration adverse effects, Pelvic Neoplasms pathology, Pelvic Neoplasms radiotherapy, Postoperative Complications mortality, Probability, Prognosis, Proportional Hazards Models, Quality of Life, Radiotherapy, Adjuvant, Rectal Neoplasms mortality, Rectal Neoplasms pathology, Rectal Neoplasms radiotherapy, Rectal Neoplasms surgery, Retrospective Studies, Risk Assessment, Survival Analysis, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms radiotherapy, Uterine Cervical Neoplasms surgery, Neoplasm Invasiveness pathology, Neoplasm Recurrence, Local mortality, Pelvic Exenteration methods, Pelvic Neoplasms mortality, Pelvic Neoplasms surgery
- Abstract
Introduction: Complete resection is the most important prognostic factor in surgery for pelvic tumors. In locally advanced and recurrent pelvic malignancies, radical margins are sometimes difficult to obtain because of close relation to or growth in adjacent organs/structures. Total pelvic exenteration (TPE) is an exenterative operation for these advanced tumors and involves en bloc resection of the rectum, bladder, and internal genital organs (prostate/seminal vesicles or uterus, ovaries and/or vagina)., Methods: Between 1994 and 2008, a TPE was performed in 69 patients with pelvic cancer; 48 with rectal cancer (32 primary and 16 recurrent), 14 with cervical cancer (1 primary and 13 recurrent), 5 with sarcoma (3 primary and 2 recurrent), 1 with primary vaginal, and 1 with recurrent endometrial carcinoma. Ten patients were treated with neoadjuvant chemotherapy and 66 patients with preoperative radiotherapy to induce down-staging. Eighteen patients received IORT because of an incomplete or marginal complete resection., Results: The median follow-up was 43 (range, 1-196) months. Median duration of surgery was 448 (range, 300-670) minutes, median blood loss was 6,300 (range, 750-21,000) ml, and hospitalization was 17 (range, 4-65) days. Overall major and minor complication rates were 34% and 57%, respectively. The in-hospital mortality rate was 1%. A complete resection was possible in 75% of all patients, a microscopically incomplete resection (R1) in 16%, and a macroscopically incomplete resection (R2) in 9%. Five-year local control for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 89%, 38%, and 64%, respectively. Overall survival after 5 years for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 66%, 8%, and 45%., Conclusions: Total pelvic exenteration is accompanied with considerable morbidity, but good local control and acceptable overall survival justifies the use of this extensive surgical technique in most patients, especially patients with primary locally advanced rectal cancer and recurrent cervical cancer.
- Published
- 2009
- Full Text
- View/download PDF
42. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
- Author
-
Kompier LC, van der Aa MN, Lurkin I, Vermeij M, Kirkels WJ, Bangma CH, van der Kwast TH, and Zwarthoff EC
- Subjects
- Adult, Aged, Aged, 80 and over, Chi-Square Distribution, Clone Cells, Cystoscopy, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms pathology, DNA Mutational Analysis, Neoplasm Recurrence, Local genetics, Receptor, Fibroblast Growth Factor, Type 3 genetics, Urinary Bladder Neoplasms genetics
- Abstract
Non-muscle invasive bladder cancers (NMI-BCs) represent 75% of bladder cancers upon presentation. After removal of the primary tumour by transurethral resection, multiple recurrences continue to develop in 70% of patients. Consequently, prolonged and costly surveillance by cystoscopy is required. Mutations in the FGFR3 oncogene are common in NMI-BCs and are associated with a lower chance of progression to muscle-invasive disease. Here we analysed the consistency of FGFR3 mutations in primary and recurrent tumours. This knowledge is of crucial importance if FGFR3 mutation analysis on urinary cells is to be used as an alternative for cystoscopical surveillance. To this end, we monitored the disease process and FGFR3 mutation status of primary and recurrent tumours in 118 patients with NMI-BC. During median follow-up of 8.8 years, these patients underwent 2133 cystoscopies and 80 patients developed 414 recurrences. FGFR3 mutations were equally prevalent in primary and recurrent tumours (63%). Patients can have different types of FGFR3 mutations in different tumours. Recurrence risk was not significantly different for patients with a mutant or wild-type primary tumour. Recurrence rates varied widely between patients but were constant for a patient and were unrelated to FGFR3 status. In the mutant patient group, in contrast to the wild-type group, recurrences continued to develop after 10 years. In 81% of the recurrences of patients with a mutant primary tumour, a mutation was found. Moreover, recurrences in this patient group were of lower stage and grade than those of patients with a wild-type primary tumour (p < 0.001). These results suggest that surveillance by FGFR3 mutation analysis on voided urine in combination with a reduced cystoscopy frequency of patients presenting with an FGFR3 mutant tumour is worth investigating.
- Published
- 2009
- Full Text
- View/download PDF
43. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
- Author
-
van der Aa MN, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA, van Exsel AJ, Kirkels WJ, Bangma C, and van der Kwast TH
- Subjects
- Cost-Benefit Analysis, Feasibility Studies, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local diagnosis, Predictive Value of Tests, Prospective Studies, Carcinoma, Transitional Cell urine, DNA urine, Microsatellite Repeats, Neoplasm Recurrence, Local urine, Urinary Bladder Neoplasms urine
- Abstract
Background: Microsatellite analysis (MA) of voided-urine samples has been promoted as an alternative for cystoscopy surveillance (UCS) of patients with low-grade non-muscle-invasive papillary urothelial carcinoma (UC)., Objective: To assess the feasibility and clinical utility of MA on voided-urine samples in a routine setting to detect or predict bladder cancer recurrences., Design, Setting, and Participants: We evaluated 228 patients monitored by MA of voided-urine samples and synchronous UCS who participated in a longitudinal prospective study in 10 hospitals. Follow-up started after diagnosis of a primary or recurrent pTa, pT1, grade 1 or grade 2 papillary UC., Measurements: Clinico-pathological parameters and fibroblast growth factor receptor 3 (FGFR3) gene mutation status of the inclusion tumour were determined. MA outcome was analysed in 1012 urine samples during a mean follow-up of 41 mo. Poor DNA quality prevented MA in 19% (197/1012) of the samples, leaving 815 visits for a cross-sectional analysis of sensitivity and specificity. We determined the predictive value (PPV) in a longitudinal analysis for 458 series with persistent MA results. Factors influencing diagnostic quality of MA were investigated. Kaplan-Meier analysis was performed to relate MA results to recurrence., Results and Limitations: Cross-sectional sensitivity and specificity of MA for detection of a recurrence were 58% (49/84) and 73% (531/731), respectively. One pT1 grade 3 UC was missed. In a longitudinal analysis, the 2-yr risk to develop a recurrence reached 83% if MA outcome was persistently positive and 22% when MA was persistently negative. PPV of MA was higher with wild-type FGFR3 gene status and smoking habits. All four upper urinary tract tumours detected were preceded by a positive MA test., Conclusions: Consecutive positive MA results are a strong predictor for future recurrences, but sensitivity needs to be improved, for example, by patient selection and testing of additional genetic markers in urine samples.
- Published
- 2009
- Full Text
- View/download PDF
44. Deformation of prostate and seminal vesicles relative to intraprostatic fiducial markers.
- Author
-
van der Wielen GJ, Mutanga TF, Incrocci L, Kirkels WJ, Vasquez Osorio EM, Hoogeman MS, Heijmen BJ, and de Boer HC
- Subjects
- Algorithms, Biomarkers, Humans, Male, Observer Variation, Phantoms, Imaging, Prostatic Neoplasms diagnostic imaging, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Computer-Assisted, Radiotherapy, Conformal, Tomography, X-Ray Computed, Urinary Bladder, Prostate abnormalities, Prostate diagnostic imaging, Prostatic Neoplasms radiotherapy, Seminal Vesicles diagnostic imaging, Seminal Vesicles pathology
- Abstract
Purpose: To quantify the residual geometric uncertainties after on-line corrections with intraprostatic fiducial markers, this study analyzed the deformation of the prostate and, in particular, the seminal vesicles relative to such markers., Patients and Methods: A planning computed tomography (CT) scan and three repeat CT scans were obtained for 21 prostate cancer patients who had had three to four cylindrical gold markers placed. The prostate and whole seminal vesicles (clinical target volume [CTV]) were delineated on each scan at a slice thickness of 1.5 mm. Rigid body transformations (translation and rotation) mapping the markers onto the planning scan positions were obtained. The translation only (T(only)) or both translation and rotation were applied to the delineated CTVs. Next, the residue CTV surface displacements were determined using nonrigid registration of the delineated contours. For translation and rotation of the CTV, the residues represented deformation; for T(only), the residues stemmed from deformation and rotation. T(only) represented the residues for most currently applied on-line protocols. The patient and population statistics of the CTV surface displacements were calculated. The intraobserver delineation variation was similarly quantified using repeat delineations for all patients and corrected for., Results: The largest CTV deformations were observed at the anterior and posterior side of the seminal vesicles (population average standard deviation =3 mm). Prostate deformation was small (standard deviation =1 mm). The increase in these deviations when neglecting rotation (T(only)) was small., Conclusion: Although prostate deformation with respect to implanted fiducial markers was small, the corresponding deformation of the seminal vesicles was considerable. Adding marker-based rotational corrections to on-line translation corrections provided a limited reduction in the estimated planning margins.
- Published
- 2008
- Full Text
- View/download PDF
45. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
- Author
-
Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, Wieland WF, Hofstaedter F, Hartmann A, and Zwarthoff EC
- Subjects
- Aged, Disease Progression, Female, Humans, Male, Prognosis, Prospective Studies, Carcinoma, Transitional Cell genetics, Carcinoma, Transitional Cell pathology, Mutation, Receptor, Fibroblast Growth Factor, Type 3 genetics, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology
- Abstract
Objectives: The clinical management of non-muscle-invasive urothelial cell carcinoma of the bladder (UCC) is challenging, as it has a marked tendency to recur and to progress. Aim of this study was to investigate the prognostic value of the WHO 1973 and 2004 grading systems and biomarkers FGFR3, CK20 and Ki-67., Methods: In a prospective study, tumours from 221 patients were studied for the expression of CK20 and Ki-67 by immunohistochemistry, and FGFR3 status by SNaPshot mutation detection. Staging and grading were performed according to the WHO classification systems of 1973 and 2004., Results: : Median follow-up was 35 mo. Recurrence occurred in 72 of 221 patients. None of the parameters was able to predict disease recurrence. CK20, Ki-67, FGFR3 mutation, molecular grade using FGFR3 mutation analysis and Ki-67, and histological grading and staging were significantly associated with disease progression in stage. In multivariable analyses, WHO 1973 and 2004 grading systems remained statistically significant and independent predictors of progression, with p=0.005 for WHO 1973 and p=0.004 for 2004. FGFR3 status was able to discriminate progressors from nonprogressors in a subset of patients with high-grade UCC (p=0.009)., Conclusions: This is the first prospective study comparing the WHO 1973 and 2004 grading systems. We show that both grading systems contribute valuable independent information. Therefore, it should be considered whether a better grading system could be developed that incorporates essential elements from both. The combination of WHO 2004 grading with FGFR3 status allows a better risk stratification for patients with high-grade non-muscle-invasive UCC.
- Published
- 2008
- Full Text
- View/download PDF
46. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison.
- Author
-
van der Aa MN, Steyerberg EW, Sen EF, Zwarthoff EC, Kirkels WJ, van der Kwast TH, and Essink-Bot ML
- Subjects
- Adaptation, Psychological, Aged, Carcinoma, Transitional Cell pathology, Cystoscopy adverse effects, Disease Progression, Female, Humans, Male, Microsatellite Repeats, Pain etiology, Perception, Quality of Life, Surveys and Questionnaires, Urinary Bladder Neoplasms pathology, Attitude to Health, Carcinoma, Transitional Cell psychology, Cystoscopy psychology, Pain psychology, Patient Satisfaction, Urinary Bladder Neoplasms psychology
- Abstract
Objective: To compare, in patients with non-muscle-invasive low-grade (pTa/pT1, G1/G2) urothelial cell carcinoma of the urinary bladder, the perceived burden of flexible cystoscopy or surveillance by microsatellite analysis (MA) in voided urine, as such patients are normally recommended to adhere to regular cysto-urethroscopic surveillance (CUS)., Patients and Methods: In all, 220 participants of a randomized trial comparing CUS and surveillance by MA were asked to complete questionnaires 1 week after cystoscopy or urine sample collection. We assessed the discomfort and pain reported during CUS, experiences with MA, and physical symptoms, medical consumption and general functioning in the week after CUS/urine sampling., Results: We analysed data from 732 questionnaires (197 patients) completed after CUS and 184 (67 patients) after collecting urine. The introduction of the cystoscope was reported to cause discomfort in 39% and pain in 35% of the responses to the questionnaires; the waiting time for the results of MA was reported as burdensome in 19%. Painful micturition was significantly more frequent in the week after CUS than after MA (30% and 12%, respectively). The frequency of fever (1% and 2%) and haematuria (7% and 6%) was similar in both groups. Older patients reported significantly less pain and discomfort from cystoscopy, and this was not related to having more previous cystoscopies., Conclusion: CUS caused pain and discomfort in about a third of patients. The burden of MA appeared fully attributable to the waiting time for the test result. The present results are a further motivation in the search for less invasive surveillance tests.
- Published
- 2008
- Full Text
- View/download PDF
47. Pelvic exenteration for primary and recurrent gynaecological malignancies.
- Author
-
de Wilt JH, van Leeuwen DH, Logmans A, Verhoef C, Kirkels WJ, Vermaas M, and Ansink AC
- Subjects
- Adult, Aged, Disease-Free Survival, Female, Humans, Middle Aged, Morbidity, Netherlands epidemiology, Pelvic Exenteration mortality, Postoperative Complications epidemiology, Retrospective Studies, Genital Neoplasms, Female surgery, Neoplasm Recurrence, Local surgery, Pelvic Exenteration adverse effects
- Abstract
Objective: Analyse the outcome of pelvic exenteration for gynaecological malignancies in a tertiary referral center. Post-operative in-hospital morbidity, long-term morbidity, disease free and overall survival rates were studied., Study Design: Between 1991 and 2004, 42 patients underwent an anterior, total or posterior exenteration for gynaecological malignancies. Follow-up was obtained from patient files; disease free and overall survival were calculated and prognostic factors were studied., Results: A pelvic exenteration was performed in 14 patients for primary and 28 patients for recurrent gynaecological cancers. In-hospital complications occurred in 19 patients (45%) of whom seven patients needed a reoperation (17%). Late complications occurred in 31 patients (75%); 21 reinterventions were performed (50%). Five-year disease free and overall survival was, respectively, 48 and 52%. Age, type of surgery, histology, localisation of the tumour, lateral wall involvement, completeness of resection and primary versus recurrent cancer were not identified as prognostic factors for recurrence or survival., Conclusion: Long-term survival is possible in about 50% of patients after pelvic exenteration for gynaecological cancers, but is associated with significant post-operative morbidity.
- Published
- 2007
- Full Text
- View/download PDF
48. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer.
- Author
-
Vermaas M, Ferenschild FT, Verhoef C, Nuyttens JJ, Marinelli AW, Wiggers T, Kirkels WJ, Eggermont AM, and de Wilt JH
- Subjects
- Adult, Aged, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local radiotherapy, Neoplasm Recurrence, Local surgery, Neoplasm Staging, Postoperative Complications, Prognosis, Proportional Hazards Models, Rectal Neoplasms pathology, Rectal Neoplasms radiotherapy, Survival Rate, Treatment Outcome, Pelvic Exenteration methods, Rectal Neoplasms surgery
- Abstract
Aims: To report the role of total pelvic exenteration in a series of locally advanced and recurrent rectal cancers., Methods: In the period 1994-2004, TPE was performed in 35 of 296 patients with primary locally advanced and recurrent rectal cancer treated in the Daniel den Hoed Cancer Center; 23 of 176 with primary locally advanced and 12 of 120 with recurrent rectal cancer. All but one patient received pre-operative External Beam Radiation Therapy (EBRT). After 1997, Intra Operative Radiotherapy (IORT) was performed in case of a resection margin less than 2 mm., Results: Overall major complication rates were not significantly different between patients with primary and recurrent rectal cancer (26% vs. 50%, p=0.94). The hospital mortality rate was 3%. The 5-year local control and overall survival of patients with primary locally advanced rectal cancer were 88% and 52%, respectively. In patients with recurrent rectal cancer 3-year local control and survival rates were 60% and 32%, respectively. An incomplete resection, preoperative pain and advanced Wanebo stage for recurrent cancer were negative prognostic factors for both local control and overall survival., Conclusion: TPE in primary locally advanced rectal cancer enables good local control and acceptable overall survival, thereby justifying the use of the procedure. Patients with recurrent rectal cancer showed a high rate of major complications, a high distant metastasis rate, and a poor overall survival.
- Published
- 2007
- Full Text
- View/download PDF
49. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
- Author
-
van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast TH, Kirkels WJ, and Schröder FH
- Subjects
- Aged, Humans, Male, Middle Aged, Prognosis, Prostatic Neoplasms epidemiology, Time Factors, Prostatic Neoplasms diagnosis
- Abstract
Objectives: To evaluate the tumor characteristics and prognostic factors in screen-detected prostate cancers in two successive screening rounds with a 4-year screening interval in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam., Methods: From 1993 to 2000, 42,376 men (21,210 in the screening arm and 21,166 in the control arm) were randomized and screened. Prostate-specific antigen testing, digital rectal examination, transrectal ultrasonography, and sextant biopsies were offered to the participants in the screening arm. A total of 1218 men with a biopsy indication at the first screening received an additional screening after 1 year (early recall). By 2004, all men had received their second screening. Interval carcinomas were defined as cancers detected during the screening interval and were identified by linkage with the Cancer Registry., Results: In the first round, 1014 prostate cancers were detected--24 in the men noncompliant to screening, 63 at the early recall screening, and 433 in the second round of screening. Also, 62 interval carcinomas were diagnosed. In the second screening round, the mean prostate-specific antigen value was lower (5.6 versus 11.1 ng/mL), advanced clinical stage T3-T4 was 7.1-fold less common, and 76.4% versus 61.5% of the biopsy Gleason scores were less than 7. In the first screening round, 13 regional and 9 distant metastases were detected; in the second round, 2 cases with distant metastasis were found., Conclusions: Overall, a shift toward more favorable tumor characteristics was seen for the second round of screening. These results support the screening methods used and the interscreening interval of 4 years.
- Published
- 2006
- Full Text
- View/download PDF
50. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
- Author
-
Chaplin BJ, Wildhagen MF, Schroder FH, Kirkels WJ, and Bangma CH
- Subjects
- Adult, Aged, Biomarkers, Tumor blood, Cohort Studies, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Invasiveness pathology, Neoplasm Recurrence, Local mortality, Neoplasm Staging, Probability, Prospective Studies, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Prostatic Neoplasms surgery, Survival Rate, Treatment Outcome, Digital Rectal Examination statistics & numerical data, Neoplasm Recurrence, Local diagnosis, Prostate-Specific Antigen blood, Prostatectomy methods, Prostatic Neoplasms diagnosis, Unnecessary Procedures
- Abstract
Objectives: We determined the role of Digital Rectal Examination (DRE) in the follow-up of those patients treated with radical prostatectomy for clinically localised prostate cancer having an undetectable PSA. We discuss the implications of our findings., Materials and Methods: An analysis was performed of a prospectively organised data base of 1118 patients treated at our institution by radical prostatectomy after the introduction of PSA in 1987. A strict definition of PSA progression was used, that is any elevation above undetectable PSA or lowest recorded post-operative PSA (nadir), in order not to miss a single patient who may have recurrent local disease or distant metastases without PSA progression. We counted local recurrent disease as those patients having histologically proven adenocarcinoma on TRUS directed biopsies, and distant disease as those patients having detectable metastatic disease on radionuclide bone scan., Results: The median follow-up was 4.0 years (3 months to 15 years). 524 men (46.9%) had a follow-up of more than 5 years and 88 men (7.9%) of more than 10 years. A total of 397 men (35.5%) had biochemical progression according to our strict definition. 53 patients (4.7%) developed a histological local recurrence and 57 men (5.1%) developed bony metastases; none of these men had an undetectable PSA or a stable PSA at nadir level at the time of detection. They all demonstrated a rising PSA., Conclusions: DRE is no longer necessary in the routine follow-up of patients with an undetectable PSA after radical prostatectomy. Following a period of approximately 2 years of out-patient clinic follow-up post-operatively in which issues such as incontinence and erectile dysfunction are addressed and treated, it is possible to restrict follow-up to PSA determinations alone and as long as the PSA remains undetectable counselling can be carried out by a nurse practitioner.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.